Theravance Biopharma Inc

NASDAQ:TBPH   3:50:50 PM EDT
7.15
+0.29 (+4.23%)
Layoffs, Restructuring / Reorganization, Earnings Announcements

Theravance Biopharma To Reduce Headcount By About 75%

Published: 09/15/2021 10:23 GMT
Theravance Biopharma Inc (TBPH) - Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio.
Theravance Biopharma Inc - Implements Significant Cost Reduction Program.
Theravance Biopharma Inc - Expects to Be Sustainably Cash Flow Positive Beginning 2h 2022.
Theravance Biopharma Inc - Headcount Will Be Reduced by Approximately 75%.
Theravance Biopharma Inc - Total Annualized Operating Expense Savings of Approximately $165 Million in 2022.
Theravance Biopharma Inc - 75% of Workforce Reduction Expected to Be Completed in November 2021 and Remainder to Be Completed in February 2022.
Theravance Biopharma Inc - Will Halt Development of All Non-respiratory Disease Related Programs.
Theravance Biopharma Inc - Decided to Reduce Size of Its Board, and Announcing Resignations From Board of George M. Whitesides and Robert V. Gunderson.
Revenue is expected to be $14.69 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $16.8 Million
Next Quarter EPS Guidance is expected to be -$0.29

More details on our Analysts Page.